Protection against the coronavirus is waning among those who have received both shots of the AstraZeneca and Pfizer vaccines, a new U.K. study has found.
An analysis from the U.K.’s ZOE Covid app study of over 400,000 people who had received both shots of the Pfizer–BioNTech vaccine, showed that it was 88% effective in protecting against the coronavirus a month after receiving both shots. However, its effectiveness fell to 74% five or six months after receiving both doses of the Pfizer vaccine.
The data was collected after May 26, when the delta variant became the dominant strain, said Tim Spector, who is running the ongoing ZOE Covid app study.
Spector, a professor of genetic epidemiology at King’s College London, presented this latest data during a webinar on Tuesday and said that the findings showed a “reduced benefit” of protection from both of these vaccines as the months progress.
Nearly 42 million people in the U.K., 77% of the population aged over 16, have received two doses of a Covid vaccine, according to government data last updated on Tuesday. The daily data showed 30,838 Covid-19 infections had been recorded on Tuesday, while 174 people had died within 28 days of testing positive for the virus.
Alexander Hammers, a professor of imaging and neuroscience at King’s College London, said on the webinar it was already known from other coronaviruses that immunity against the disease didn’t tend to be lifelong.
And even though the data did show a “waning” in the effectiveness of the vaccines over time, Hammers said that people were “still probably at least 50% protected.”
“Remember when the vaccines were first developed it was hoped that they were to have 60%-70% efficacy and everybody was pleasantly surprised that they came in well over 80%, sometimes well over 90,” he added.
Nevertheless, Spector said he was still “a bit worried” by coronavirus data coming out of Israel, which had one of the fastest vaccination programs in the world and was ahead of the U.K.
He pointed out that Israel was starting to see increased hospitalizations and deaths from the coronavirus, despite a large proportion of its population being vaccinated.
Data published by Israel in July, showed that the Pfizer vaccine was just 16% effective against symptomatic infection for those individuals who received two doses in January.
Comparing results is tricky, however, given differences in the nature of the vaccination programs in different countries, as well as differences in study dates, age groups and Covid testing regimes.
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble [...]
A technology developed at Vanderbilt University Medical Center has led to the discovery of an "ultra-potent" monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. The antibody [...]
Research has found a significant fall in levels of antibodies against SARS-CoV-2, the virus that causes COVID-19, 6 months after the second dose of the Pfizer-BioNTech vaccine. Clinical evidence also suggests that the risk [...]
Are the COVID vaccines substantially different from/inferior to other vaccines in terms of their effectiveness? The issue raised, and I'm mostly paraphrasing here, is this: Most vaccines (e.g. measles, smallpox) have efficacy defined such [...]
The EVONANO platform allows scientists to grow virtual tumors and use artificial intelligence to automatically optimize the design of nanoparticles to treat them. The ability to grow and treat virtual tumors is an [...]
Modern Approaches to Augmentation of Brain Function Available from Springer Press This book covers recent advances in neural technology that provide for enhancements for brain function. It addresses a broad range of neural phenomena [...]
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution. A recent study tested the efficacy of a new adeno-associated virus (AAV) [...]
Fully vaccinated people were 11 times less likely to die of COVID and 10 times less likely to be hospitalized compared to the unvaccinated since highly contagious Delta became the most common variant, US [...]
The highly-infectious Delta coronavirus variant has spread to at least 174 countries worldwide, from the US to Australia, causing a surge in COVID-19 cases. The variant has mutations that help it partially escape the immune response produced by [...]
Fragile mRNA molecules used in COVID-19 vaccines can’t get into cells on their own. They owe their success to lipid nanoparticles that took decades to refine. Messenger RNA (mRNA) is having a moment. This [...]
The COVID-19 pandemic has revealed critical knowledge gaps and assumptions concerning how respiratory viruses spread between hosts. Traditionally thought to be spread mainly through large respiratory droplets produced by the coughs and sneezes of sick individuals, [...]
SARS-CoV-2 is just one of nonillions of viruses on our planet, and scientists are rapidly identifying legions of new species. Mya Breitbart has hunted novel viruses in African termite mounds, Antarctic seals and water [...]
As a team of South African researchers we have identified a new lineage of SARS-CoV-2, the virus causing COVID-19. A lineage represents a genetically distinct virus population with a common ancestor. This virus may be designated as a variant [...]